220 related articles for article (PubMed ID: 20075157)
1. A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.
Khandanpour C; Thiede C; Valk PJ; Sharif-Askari E; Nückel H; Lohmann D; Horsthemke B; Siffert W; Neubauer A; Grzeschik KH; Bloomfield CD; Marcucci G; Maharry K; Slovak ML; van der Reijden BA; Jansen JH; Schackert HK; Afshar K; Schnittger S; Peeters JK; Kroschinsky F; Ehninger G; Lowenberg B; Dührsen U; Möröy T
Blood; 2010 Mar; 115(12):2462-72. PubMed ID: 20075157
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.
Botezatu L; Michel LC; Helness A; Vadnais C; Makishima H; Hönes JM; Robert F; Vassen L; Thivakaran A; Al-Matary Y; Lams RF; Schütte J; Giebel B; Görgens A; Heuser M; Medyouf H; Maciejewski J; Dührsen U; Möröy T; Khandanpour C
Exp Hematol; 2016 Aug; 44(8):713-726.e14. PubMed ID: 27216773
[TBL] [Abstract][Full Text] [Related]
3. Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS).
Xie X; Frank D; Patnana PK; Schütte J; Al-Matary Y; Liu L; Wei L; Dugas M; Varghese J; Nimmagadda SC; Khandanpour C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008835
[TBL] [Abstract][Full Text] [Related]
4. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
Frank D; Patnana PK; Vorwerk J; Mao L; Gopal LM; Jung N; Hennig T; Ruhnke L; Frenz JM; Kuppusamy M; Autry R; Wei L; Sun K; Mohammed Ahmed HM; Künstner A; Busch H; Müller H; Hutter S; Hoermann G; Liu L; Xie X; Al-Matary Y; Nimmagadda SC; Cano FC; Heuser M; Thol F; Göhring G; Steinemann D; Thomale J; Leitner T; Fischer A; Rad R; Röllig C; Altmann H; Kunadt D; Berdel WE; Hüve J; Neumann F; Klingauf J; Calderon V; Opalka B; Dührsen U; Rosenbauer F; Dugas M; Varghese J; Reinhardt HC; von Bubnoff N; Möröy T; Lenz G; Batcha AMN; Giorgi M; Selvam M; Wang E; McWeeney SK; Tyner JW; Stölzel F; Mann M; Jayavelu AK; Khandanpour C
Blood; 2023 Dec; 142(25):2175-2191. PubMed ID: 37756525
[TBL] [Abstract][Full Text] [Related]
5. GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.
Botezatu L; Michel LC; Makishima H; Schroeder T; Germing U; Haas R; van der Reijden B; Marneth AE; Bergevoet SM; Jansen JH; Przychodzen B; Wlodarski M; Niemeyer C; Platzbecker U; Ehninger G; Unnikrishnan A; Beck D; Pimanda J; Hellström-Lindberg E; Malcovati L; Boultwood J; Pellagatti A; Papaemmanuil E; Le Coutre P; Kaeda J; Opalka B; Möröy T; Dührsen U; Maciejewski J; Khandanpour C
Exp Hematol; 2016 Jul; 44(7):590-595.e1. PubMed ID: 27080012
[TBL] [Abstract][Full Text] [Related]
6. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
[TBL] [Abstract][Full Text] [Related]
7. The t(8;21) chromosomal translocation in acute myelogenous leukemia modifies intranuclear targeting of the AML1/CBFalpha2 transcription factor.
McNeil S; Zeng C; Harrington KS; Hiebert S; Lian JB; Stein JL; van Wijnen AJ; Stein GS
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):14882-7. PubMed ID: 10611307
[TBL] [Abstract][Full Text] [Related]
8. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
[TBL] [Abstract][Full Text] [Related]
9. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
[TBL] [Abstract][Full Text] [Related]
10. GFI1 is required for
Marneth AE; Botezatu L; Hönes JM; Israël JCL; Schütte J; Vassen L; Lams RF; Bergevoet SM; Groothuis L; Mandoli A; Martens JHA; Huls G; Jansen JH; Dührsen U; Berg T; Möröy T; Wichmann C; Lo MC; Zhang DE; van der Reijden BA; Khandanpour C
Haematologica; 2018 Sep; 103(9):e395-e399. PubMed ID: 29674496
[No Abstract] [Full Text] [Related]
11. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
Müller-Tidow C; Steffen B; Cauvet T; Tickenbrock L; Ji P; Diederichs S; Sargin B; Köhler G; Stelljes M; Puccetti E; Ruthardt M; deVos S; Hiebert SW; Koeffler HP; Berdel WE; Serve H
Mol Cell Biol; 2004 Apr; 24(7):2890-904. PubMed ID: 15024077
[TBL] [Abstract][Full Text] [Related]
12. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
[TBL] [Abstract][Full Text] [Related]
13. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
[TBL] [Abstract][Full Text] [Related]
14. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
15. Definition of a small core transcriptional circuit regulated by AML1-ETO.
Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia.
Le XF; Claxton D; Kornblau S; Fan YH; Mu ZM; Chang KS
Eur J Haematol; 1998 Apr; 60(4):217-25. PubMed ID: 9579874
[TBL] [Abstract][Full Text] [Related]
17. Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival.
Dayyani F; Wang J; Yeh JR; Ahn EY; Tobey E; Zhang DE; Bernstein ID; Peterson RT; Sweetser DA
Blood; 2008 Apr; 111(8):4338-47. PubMed ID: 18258796
[TBL] [Abstract][Full Text] [Related]
18. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
[TBL] [Abstract][Full Text] [Related]
19. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor.
Wildonger J; Mann RS
Development; 2005 May; 132(10):2263-72. PubMed ID: 15829516
[TBL] [Abstract][Full Text] [Related]
20. The leukemia associated ETO nuclear repressor gene is regulated by the GATA-1 transcription factor in erythroid/megakaryocytic cells.
Ajore R; Dhanda RS; Gullberg U; Olsson I
BMC Mol Biol; 2010 May; 11():38. PubMed ID: 20487545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
